The neuroendocrine response to stress is a dynamic process

Area of Science:

• Endocrinology
• Critical Care Medicine
• Neuroendocrinology

Background:

• The initial neuroendocrine response to critical illness involves activated anterior pituitary function, considered adaptive.
• Previously, the acute stress response was assumed to persist throughout critical illness, but this is now disproven.
• Protracted critical illness is characterized by reduced pulsatile secretion of pituitary hormones, impairing target organ function.

Purpose of the Study:

• To investigate the neuroendocrine changes in protracted critical illness.
• To explore therapeutic strategies for restoring pituitary function and improving metabolic outcomes.

Main Methods:

• Observation of reduced pulsatile secretion of growth hormone, thyroid-stimulating hormone, prolactin, and luteinizing hormone in protracted critical illness.
• Assessment of the role of reduced releasing hormones (thyrotropin-releasing hormone, gonadotropin-releasing hormone, ghrelin, growth hormone-releasing hormone).
• Administration of combinations of releasing factors to re-establish hormone secretion and assess metabolic effects.

Main Results:

• Reduced availability of key releasing hormones contributes to impaired pituitary function in chronic critical illness.
• Combined administration of growth hormone-secretagogues, thyrotropin-releasing hormone, and gonadotropin-releasing hormone re-established pulsatile hormone secretion.
• This combination therapy increased insulin-like growth factor-1, binding proteins, thyroxine, tri-iodothyronine, and testosterone levels.
• Metabolic alterations were beneficial with combined therapy, unlike minor effects and side-effects of single-hormone treatments.

Conclusions:

• Protracted critical illness involves a selective reduction in pituitary stimulation, not a persistent acute stress response.
• Combined releasing factor therapy offers a novel therapeutic approach to reverse the wasting syndrome and reduce intensive care dependency.
• This strategy normalizes hormone secretion and improves metabolic status in critically ill patients.